Thousands of people are suing Bayer over Roundup weed killer because they believe exposure to the herbicide caused them to develop non-Hodgkin lymphoma, a serious cancer. The lawsuits stem from decades of product use, with many claimants arguing that Bayer—which acquired Roundup’s original manufacturer Monsanto in 2018—knew or should have known about the cancer risks but failed to provide adequate warnings on product labels. In February 2026, Bayer announced a landmark $7.25 billion settlement agreement to resolve current and future Roundup-related cancer claims, marking one of the largest mass tort settlements in U.S. history.
The sheer volume of litigation reflects widespread concern about Roundup’s safety. As of June 2026, more than 60,000 active lawsuits remain pending, even after the settlement agreement received preliminary judicial approval. This number alone demonstrates how many people believe their cancer diagnosis is connected to Roundup exposure—whether through occupational use, household application, or environmental contact. The settlement offers compensation ranging from $6,000 to $165,000 depending on factors such as exposure history, age at diagnosis, and cancer severity, with payments extending over up to 21 years.
Table of Contents
- What Is Non-Hodgkin Lymphoma and Why Do People Link It to Roundup?
- How Did the Scale of Roundup Litigation Grow So Dramatically?
- What Are the Details of the $7.25 Billion Settlement Agreement?
- Who Is Eligible for the Roundup Settlement and How Do You Claim?
- What Was the June 2026 Supreme Court Decision and What Does It Mean?
- What Are the Actual Payout Amounts and What Factors Determine Them?
- What Happens to the 60,000 Remaining Active Roundup Lawsuits?
What Is Non-Hodgkin Lymphoma and Why Do People Link It to Roundup?
Non-Hodgkin lymphoma (NHL) is a type of blood cancer that develops in lymph cells, part of the immune system. Symptoms can include swollen lymph nodes, fatigue, fever, and night sweats, and treatment typically involves chemotherapy, radiation, or immunotherapy. Unlike some cancers with clear, established causes, NHL can develop from multiple risk factors, but a growing body of evidence suggested a possible link between Roundup exposure and NHL development.
The legal cases center on glyphosate, Roundup’s active ingredient, which has been the subject of scientific debate for years. Some studies have suggested increased NHL risk among people with substantial glyphosate exposure, particularly farmers, agricultural workers, and professional landscapers who handled the chemical regularly over many years. However, regulatory agencies in multiple countries have reached different conclusions about glyphosate safety, creating a legal landscape where plaintiffs argue bayer should have disclosed potential risks more prominently on labels and marketing materials. A farmer in Iowa who developed NHL after decades of applying Roundup to crop fields represents a typical claimant profile in these lawsuits.
How Did the Scale of Roundup Litigation Grow So Dramatically?
Roundup is one of the most widely used herbicides in the world, with billions of applications across agricultural, commercial, and residential settings since its introduction in 1974. The sheer number of potential exposures meant that if a genuine link to cancer existed, the pool of affected people would be enormous. As awareness grew about the potential health risks, particularly following some successful verdicts against Bayer in individual trials, more people came forward with claims, and personal injury attorneys began taking on Roundup cases in large numbers.
The litigation also accelerated after Monsanto’s acquisition by Bayer, as claims that had been pending against Monsanto automatically became Bayer’s responsibility. A significant limiting factor in these cases is proving causation—that Roundup specifically caused a person’s NHL rather than other factors like genetics, age, or other exposures. This is why settlements typically require proof of diagnosis before a specific cutoff date (March 4, 2026, in the Bayer settlement) and often emphasize occupational or significant environmental exposure history. Nevertheless, the cumulative number of cases reached such proportions that ongoing litigation became untenable for Bayer, pushing the company toward a comprehensive settlement.
What Are the Details of the $7.25 Billion Settlement Agreement?
The $7.25 billion settlement, announced in February 2026 and granted preliminary judicial approval, is designed to compensate both people who have already been diagnosed with NHL and those who may develop Roundup-related cancer in the future. The settlement establishes a claims process and payout structure rather than awarding a lump sum to the company itself. Instead, funds are allocated to individual claimants based on their specific circumstances and the timing of their diagnosis.
One important aspect of the settlement is its long payment timeline: compensation will be distributed over up to 21 years, which allows Bayer to manage the financial impact while ensuring claimants receive their awards. This extended schedule is common in large mass tort settlements and reflects the reality that the total number of eligible claimants cannot be determined immediately. People who were diagnosed with NHL before March 4, 2026, automatically qualify for consideration, while those diagnosed after that date can claim within six years of their diagnosis, extending the settlement’s scope well into the future.
Who Is Eligible for the Roundup Settlement and How Do You Claim?
To qualify for the Bayer Roundup settlement, you must have a confirmed diagnosis of non-Hodgkin lymphoma. The settlement sets March 4, 2026, as the cutoff date for already-diagnosed cases—anyone diagnosed before that date is eligible to file a claim. For people diagnosed after March 4, 2026, a six-year window applies, meaning you can claim within six years of your diagnosis date.
The settlement also accommodates future claimants, recognizing that some people exposed to Roundup today may not develop NHL until years from now. The claims process typically involves submitting medical documentation proving your NHL diagnosis, evidence of Roundup exposure (medical records, employment history, product purchase receipts, or witness testimony), and other supporting information. Claimants do not need to have won a court verdict against Bayer to receive settlement compensation—the settlement is designed specifically to resolve disputes without requiring individual trials. However, the amount of compensation you receive depends on several factors including your exposure history, age at diagnosis, and the stage and type of your NHL, which explains the wide range from $6,000 to $165,000.
What Was the June 2026 Supreme Court Decision and What Does It Mean?
On June 25, 2026, the U.S. Supreme Court issued a decision affecting Roundup litigation, ruling in Monsanto’s favor on a key labeling question. This decision narrowed one of the major arguments that plaintiffs had been pursuing in their lawsuits—specifically, claims that Roundup’s labeling was inadequate or misleading.
While this ruling provided some legal relief to Bayer and Monsanto, it did not eliminate the pending settlement or invalidate the claims of people who had already filed lawsuits. The Supreme Court’s decision illustrates an important limitation in Roundup litigation: even when plaintiffs believe they have strong evidence of health harm, federal courts apply strict standards to determine whether product labeling was actually inadequate under law. This ruling reinforced that winning individual Roundup cases is difficult, which is one reason the $7.25 billion settlement became attractive—it resolves thousands of pending claims without requiring each one to survive court scrutiny. The June ruling also explains why some people with valid health concerns may still face hurdles if they pursue litigation independently rather than through the settlement process.
What Are the Actual Payout Amounts and What Factors Determine Them?
Settlement payout amounts for the Bayer Roundup settlement range from $6,000 to $165,000, with the highest payouts reserved for claimants meeting several criteria simultaneously. People who were diagnosed before age 60, had significant professional or occupational exposure to Roundup (such as farmers or commercial applicators), and have aggressive forms of NHL typically fall into the highest payout category. In contrast, someone with limited exposure history and a less aggressive cancer diagnosis might receive a lower amount within the settlement range.
The variation in payouts reflects the reality that Roundup exposure is not uniform—a professional pesticide applicator with 30 years of daily contact faces different exposure levels than someone who occasionally used Roundup in a home garden. Settlement administrators evaluate each claim individually, weighing medical records, employment history, and other evidence to place claimants within the appropriate compensation tier. This individualized approach means that identical NHL diagnoses can result in different payments depending on the person’s exposure profile and cancer characteristics.
What Happens to the 60,000 Remaining Active Roundup Lawsuits?
As of June 2026, more than 60,000 active Roundup lawsuits remain pending in courts across the United States, even after Bayer’s settlement agreement reached preliminary approval. These cases represent people who filed suit before or after the settlement announcement and who have not yet resolved their claims. Most of these plaintiffs will have the opportunity to join the settlement process rather than continue individual litigation, though they may also elect to opt out and pursue their cases independently if they believe they have stronger claims.
The continued volume of pending litigation demonstrates that the $7.25 billion settlement, while substantial, does not represent a complete end to Roundup-related legal disputes. Some claimants may pursue their cases outside the settlement to seek higher awards, though post-Supreme Court ruling, individual verdicts are more uncertain. For most plaintiffs, however, the settlement provides a more reliable path to compensation than continuing to litigate against Bayer’s substantial legal resources, and the claims process is designed to resolve cases far more quickly than traditional lawsuits.